775.90
price down icon0.47%   -3.63
after-market Dopo l'orario di chiusura: 776.01 0.11 +0.01%
loading
Precedente Chiudi:
$779.53
Aprire:
$779.53
Volume 24 ore:
2.73M
Relative Volume:
0.70
Capitalizzazione di mercato:
$724.64B
Reddito:
$49.00B
Utile/perdita netta:
$11.11B
Rapporto P/E:
63.13
EPS:
12.29
Flusso di cassa netto:
$-1.27B
1 W Prestazione:
-0.28%
1M Prestazione:
+5.18%
6M Prestazione:
+0.51%
1 anno Prestazione:
-15.14%
Intervallo 1D:
Value
$773.00
$790.00
Intervallo di 1 settimana:
Value
$773.00
$802.50
Portata 52W:
Value
$677.09
$972.53

Lilly Eli Co Stock (LLY) Company Profile

Name
Nome
Lilly Eli Co
Name
Telefono
(317) 276-2000
Name
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
Dipendente
47,000
Name
Cinguettio
@LillyPad
Name
Prossima data di guadagno
2024-10-30
Name
Ultimi documenti SEC
Name
LLY's Discussions on Twitter

Confronta LLY con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
LLY
Lilly Eli Co
775.90 724.64B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
155.92 376.43B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
69.82 352.49B 43.59B 15.04B 10.74B 3.3766
Drug Manufacturers - General icon
ABBV
Abbvie Inc
189.99 334.73B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
123.10 234.21B 53.22B 12.86B 14.85B 6.39

Lilly Eli Co Stock (LLY) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-06-05 Downgrade Erste Group Buy → Hold
2025-04-28 Downgrade HSBC Securities Buy → Reduce
2025-04-22 Iniziato Cantor Fitzgerald Overweight
2024-12-10 Ripresa BofA Securities Buy
2024-11-15 Iniziato Wolfe Research Outperform
2024-10-17 Iniziato Bernstein Outperform
2024-09-13 Ripresa Citigroup Buy
2024-08-12 Aggiornamento Deutsche Bank Hold → Buy
2024-02-21 Downgrade DZ Bank Buy → Hold
2024-02-16 Reiterato Morgan Stanley Overweight
2023-12-21 Downgrade Daiwa Securities Buy → Outperform
2023-11-09 Iniziato Deutsche Bank Hold
2023-10-20 Ripresa UBS Buy
2023-08-09 Aggiornamento Jefferies Hold → Buy
2023-07-26 Reiterato Citigroup Buy
2023-07-14 Iniziato HSBC Securities Buy
2023-05-24 Reiterato BofA Securities Buy
2023-05-24 Reiterato UBS Buy
2023-03-13 Aggiornamento Wells Fargo Equal Weight → Overweight
2023-03-06 Iniziato Jefferies Hold
2023-02-15 Downgrade Societe Generale Hold → Sell
2022-11-18 Iniziato Credit Suisse Outperform
2022-09-22 Aggiornamento UBS Neutral → Buy
2022-05-23 Iniziato SVB Leerink Outperform
2022-04-06 Ripresa Morgan Stanley Overweight
2022-03-10 Iniziato Daiwa Securities Outperform
2022-01-21 Aggiornamento DZ Bank Hold → Buy
2022-01-03 Reiterato Bernstein Mkt Perform
2021-12-17 Iniziato Goldman Neutral
2021-12-16 Reiterato BMO Capital Markets Outperform
2021-12-16 Reiterato BofA Securities Buy
2021-12-09 Ripresa Wells Fargo Equal Weight
2021-11-19 Iniziato BMO Capital Markets Outperform
2021-10-11 Aggiornamento Berenberg Hold → Buy
2021-09-29 Aggiornamento Citigroup Neutral → Buy
2021-08-05 Aggiornamento DZ Bank Hold → Buy
2021-07-27 Ripresa Truist Buy
2021-06-24 Reiterato Cantor Fitzgerald Overweight
2021-01-19 Aggiornamento Mizuho Neutral → Buy
2020-12-10 Aggiornamento Wolfe Research Peer Perform → Outperform
2020-11-10 Ripresa Bernstein Mkt Perform
2020-09-29 Iniziato Berenberg Hold
2020-09-03 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2020-06-16 Aggiornamento Guggenheim Neutral → Buy
2020-04-21 Downgrade UBS Buy → Neutral
2020-04-09 Downgrade Morgan Stanley Overweight → Equal-Weight
2020-02-06 Iniziato Mizuho Neutral
2019-12-18 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2019-10-17 Ripresa BofA/Merrill Buy
2019-05-28 Iniziato Goldman Buy
2019-04-24 Aggiornamento Edward Jones Hold → Buy
2019-04-11 Downgrade Guggenheim Buy → Neutral
2019-03-12 Iniziato JP Morgan Overweight
2019-01-23 Iniziato UBS Buy
2018-11-26 Downgrade Citigroup Buy → Neutral
2018-10-31 Aggiornamento Credit Suisse Underperform → Neutral
2018-10-09 Iniziato Guggenheim Buy
2018-10-01 Reiterato SunTrust Buy
2018-09-26 Ripresa JP Morgan Overweight
Mostra tutto

Lilly Eli Co Borsa (LLY) Ultime notizie

pulisher
Jun 18, 2025

Lilly to appeal after UK agency opposes reimbursement for Alzheimer's drug - Reuters

Jun 18, 2025
pulisher
Jun 18, 2025

Wisner Baum: Ninth Circuit Affirms Actos RICO Class Action Certification Against Takeda and Eli Lilly - The Malaysian Reserve

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly’s SWOT analysis: stock poised for growth amid challenges in GLP-1 market - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly genetic medicine acquisition to address cardiovascular risk - European Pharmaceutical Review

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly (LLY) Enters Gene-Editing Space with Verve Therapeutics Acquisition - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly (LLY): Bariatric Surgery Outperforms GLP-1 Drugs in We - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study - Benzinga

Jun 18, 2025
pulisher
Jun 18, 2025

More Than a One Trick Pony, Lilly Feeds Success Back Into Biotech - BioSpace

Jun 18, 2025
pulisher
Jun 18, 2025

Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. - The Globe and Mail

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly Stock Dips (18 Jun): Analyzing the Drop and What Traders Should Do Next - Daily Chhattisgarh News

Jun 18, 2025
pulisher
Jun 18, 2025

UBS reiterates buy rating on Eli Lilly stock following Verve acquisition - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly stock price target maintained at $1,100 by Bernstein on Verve deal - Investing.com Canada

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug - rrdailyherald.com

Jun 18, 2025
pulisher
Jun 18, 2025

Lilly to acquire Verve Therapeutics to advance gene editing treatments - World Pharmaceutical Frontiers

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly to expand cardiovascular disease pipeline with $1.3bn Verve acquisition - PMLiVE

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly (LLY) Moves to Acquire Verve Therapeutics in $1B Deal - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly acquisition of Verve signals renewed interest in gene editing - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Lilly Eyes Future of One-Time Cardiovascular Health with $1.3B Verve Therapeutics Acquisition - geneonline.com

Jun 18, 2025
pulisher
Jun 18, 2025

Adam Parker of Trivariate Research Recommends Eli Lilly’s Dividend as a Defensive Play - Insider Monkey

Jun 18, 2025
pulisher
Jun 17, 2025

In a $1.3B deal, Lilly buys gene editor Verve - BioWorld MedTech

Jun 17, 2025
pulisher
Jun 17, 2025

Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve - insights.citeline.com

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly to buy gene-editing biotech Verve for $1.3 billion - The Boston Globe

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly Co. to buy gene-editing startup Verve to develop cardiac drugs - upi.com

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly lands "bargain" deal to acquire Verve Therapeutics for $1.3bn - Pharmaceutical Technology

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly (LLY) 5-Year Growth Surges Over 383%, Showcasing Enduring Strength Beyond Daily Market Moves - Daily Chhattisgarh News

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly LLY (NYSE:LLY) Expands Biotech Reach With Verve Deal Talks Dow Jones Industrial Average - Kalkine Media

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

UBS Maintains Price Target on Eli Lilly (LLY) Despite CVS Shift to Wegovy - Insider Monkey

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly Bets Big On Gene Editing With Verve Deal - Finimize

Jun 17, 2025
pulisher
Jun 17, 2025

Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly - TradingView

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly Acquires Verve Therapeutics In $1.3 Billion Deal - Finimize

Jun 17, 2025
pulisher
Jun 17, 2025

Lilly acquires cardiovascular genetic medicine company for up to $1.3B - Inside INdiana Business

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly to acquire gene-editing specialists focused on CVD for up to $1.3B - Cardiovascular Business

Jun 17, 2025
pulisher
Jun 17, 2025

Lilly to acquire Verve in $1B bet on gene editing for heart disease - BioPharma Dive

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly to buy Verve Therapeutics for up to $1.3 Billion - Yahoo

Jun 17, 2025
pulisher
Jun 17, 2025

Verve Therapeutics Soars 75% After Eli Lilly Buyout - Wall Street Pit

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly Expands Gene-Editing Arsenal With Verve Acquisition - Finimize

Jun 17, 2025
pulisher
Jun 17, 2025

Lilly adds highest Zepbound doses to DTC offering - STAT

Jun 17, 2025
pulisher
Jun 17, 2025

This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly to Buy Gene-Editing Biotech Verve for $1.3 Billion - Bloomberg

Jun 17, 2025
pulisher
Jun 17, 2025

Liking what it sees, Lilly to buy base editing partner Verve for $1.3B - FirstWord Pharma

Jun 17, 2025
pulisher
Jun 17, 2025

Lilly to buy gene-editing partner Verve for up to $1.3 billion in cardiac care push - Reuters

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly Stock Dives Today: A Trader’s Analysis of Key LLY Metrics - Daily Chhattisgarh News

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why - Mint

Jun 17, 2025
pulisher
Jun 17, 2025

Lilly to Acquire Verve Therapeutics for Up to $1.3B - Genetic Engineering and Biotechnology News

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly acquires biotech company for USD 1.3bn - medwatch.com

Jun 17, 2025
pulisher
Jun 17, 2025

Lilly to buy gene-editing partner Verve for up to US$1.3 billion in cardiac care push - CP24

Jun 17, 2025
pulisher
Jun 17, 2025

Verve soars after Eli Lilly announces $1.3 billion acquisition of gene-editing company - Sherwood News

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade) (NYSE:LLY) - Seeking Alpha

Jun 17, 2025

Lilly Eli Co Azioni (LLY) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Lilly Eli Co Azioni (LLY) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Yuffa Ilya
EVP & President, LLY Int'l
May 14 '25
Sale
749.24
1,250
936,550
27,510
drug_manufacturers_general JNJ
$155.92
price up icon 2.08%
drug_manufacturers_general NVO
$69.82
price up icon 1.16%
$189.99
price up icon 2.35%
drug_manufacturers_general NVS
$123.10
price up icon 1.73%
drug_manufacturers_general MRK
$81.81
price up icon 3.35%
Capitalizzazione:     |  Volume (24 ore):